Policy Change and the National Essential Medicines List Development Process in Brazil between 2000 and 2014: Has the Essential Medicine Concept been Abandoned?

Policy Change and the National Essential Medicines List Development Process in Brazil between... Brazil has had a National Essential Medicines List (EML) since 1964. From 2000 to 2010, five consecutive evidence‐based editions were produced, building on the essential medicine concept. In 2012, the government changed course to establish a new paradigm, introducing adoption of new medicines as the main aim within the recommendation process. The objective of the article was to report efforts to develop Brazil's national EML, policy changes from 2000 to 2014, discussing results, challenges and perspectives. Brazilian EML history and development process were collected from legislation, minutes, reports and legal ordinances, from 2000 to 2014. The Brazilian EML and the WHO Model Lists were compared using the Anatomical Therapeutic Chemical system. Overlap between lists was verified, and linear trends were produced. Type of membership, inclusion criteria, procedures, flow and listed medicines varied greatly between the selection committees acting before and after 2012. Paradigm‐changing legislation aiming at linking list compliance to public financing in 2012 produced (i) greater importance given to political and administrative stakeholders, (ii) increasing trends in number of medicines over the years, (iii) decrease in use of WHO Model List as a reference and (iv) substitution of an essential medicines list review and update process by an adoption decision output. Other issues remained unchanged. Insufficient efforts for list implementation, such as lack of physician education, presented consequences to the health system. Substantial efforts were made to produce and update the list from 2000 to 2014. However, continuous and intense health litigation disproves process outcome effectiveness. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Basic and Clinical Pharmacology & Toxicology Wiley

Policy Change and the National Essential Medicines List Development Process in Brazil between 2000 and 2014: Has the Essential Medicine Concept been Abandoned?

11 pages
Read Article

Loading next page...
 
/lp/wiley/policy-change-and-the-national-essential-medicines-list-development-GYCemffFqe
Publisher
Wiley Subscription Services, Inc., A Wiley Company
Copyright
Copyright © 2018 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society). Published by John Wiley & Sons Ltd
ISSN
1742-7835
eISSN
1742-7843
D.O.I.
10.1111/bcpt.12932
Publisher site
See Article on Publisher Site

Abstract

Brazil has had a National Essential Medicines List (EML) since 1964. From 2000 to 2010, five consecutive evidence‐based editions were produced, building on the essential medicine concept. In 2012, the government changed course to establish a new paradigm, introducing adoption of new medicines as the main aim within the recommendation process. The objective of the article was to report efforts to develop Brazil's national EML, policy changes from 2000 to 2014, discussing results, challenges and perspectives. Brazilian EML history and development process were collected from legislation, minutes, reports and legal ordinances, from 2000 to 2014. The Brazilian EML and the WHO Model Lists were compared using the Anatomical Therapeutic Chemical system. Overlap between lists was verified, and linear trends were produced. Type of membership, inclusion criteria, procedures, flow and listed medicines varied greatly between the selection committees acting before and after 2012. Paradigm‐changing legislation aiming at linking list compliance to public financing in 2012 produced (i) greater importance given to political and administrative stakeholders, (ii) increasing trends in number of medicines over the years, (iii) decrease in use of WHO Model List as a reference and (iv) substitution of an essential medicines list review and update process by an adoption decision output. Other issues remained unchanged. Insufficient efforts for list implementation, such as lack of physician education, presented consequences to the health system. Substantial efforts were made to produce and update the list from 2000 to 2014. However, continuous and intense health litigation disproves process outcome effectiveness.

Journal

Basic and Clinical Pharmacology & Toxicology – Wiley

Published: Jan 1, 2018

References

  • The Selection of Essential Drugs: First Report of the WHO Expert Committee
  • The concept of essential medicines: lessons for rich countries
    Hogerzeil, HV
  • Tough decisions on essential medicines in 2015
    Magrini, N; Robertson, J; Forte, G; Cappello, B; Moja, LP; Joncheere, K
  • The “Wise List”‐ a comprehensive concept to select, communicate and achieve adherence to recommendations of essential drugs in ambulatory care in Stockholm
    Gustafsson, LL; Wettermark, B; Godman, B; Andersén‐Karlsson, E; Bergman, U; Hasselström, J
  • Quality use of medicines within universal health coverage: challenges and opportunities
    Wagner, AK; Quick, JD; Ross‐Degnan, D
  • Essential medicines for universal health coverage
    Wirtz, VJ; Hogerzeil, HV; Gray, AL; Bigdeli, M; Joncheere, CP; Ewen, MA
  • High adherence to the ‘Wise List' treatment recommendations in Stockholm: a 15‐year retrospective review of a multifaceted approach promoting rational use of medicines
    Eriksen, J; Gustafsson, LL; Ateva, K; Bastholm‐Rahmner, P; Ovesjö, ML; Jirlow, M
  • Are we moving towards a new definition of essential medicines?
    Manikandan, S
  • Doctors, lawyers and pharmaceutical industry on health lawsuits in Minas Gerais, Southeastern Brazil
    Campos Neto, OH; Acurcio, FA; Machado, MAA; Ferré, F; Barbosa, FLV; Cherchiglia, ML
  • Insulin glargine in a Brazilian State: should the government disinvest? An assessment based on a systematic review
    Caires de Souza, AL; Acurcio, F; Guerra Júnior, A; do Nascimento, R; Godman, B; Diniz, M
  • Judicialisation and the right to health in Brazil
    Biehl, J; Petryna, A; Gertner, A; Amon, JJ; Picon, PD
  • Essential to increase the use of generics in Europe to maintain comprehensive healthcare?
    Godman, B; Bennie, M; Baumgärtel, C; Sović Brkičić, L; Burkhardt, T; Fürst, J
  • New drugs, new indications in 2015: little progress, and threats to access to quality healthcare for all
  • Ministry of Health's spending on drugs: program trends from 2002 to 2007
    Vieira, FS
  • Health technology performance assessment: real‐world evidence for public healthcare sustainability
    Guerra Jnr, A; Lemos, LLP; Godman, B; Bennie, M; Castro, CGO; Alvares, J
  • Medicamentos no Brasil: inovação e acesso
    Pepe, VLE; Osorio‐De‐Castro, CGS; Luiza, VL
  • Essential medicines and technology incorporation following novel Brazilian Public Health System regulations
    Santos‐Pinto, CDB; Ventura, M; Pepe, VLE; Osorio‐de‐Castro, CGS
  • The list of drugs in the Popular Pharmacy Program and the Brazilian National Pharmaceutical Care Policy
    Yamauti, SM; Barberato‐Filho, S; Lopes, LC
  • The essentiality and rationality of the Brazilian national listing of essential medicines
    Yamauti, SM; Bonfim, JRDA; Barberato‐Filho, S; Lopes, LC
  • National Medicines Policy in retrospective: a review of (almost) 20 years of implementation
    Vasconcelos, DMM; Chaves, GC; Azeredo, TB; Silva, RM
  • Essential medicines and the selection process in management practices of pharmaceutical services in Brazilian states and municipalities
    Magarinos‐Torres, R; Pepe, VLE; Oliveira, MA; Osorio‐de‐Castro, CGS
  • Advances and challenges to the Brazilian policy of health technology management
    Silva, HP; Petramale, CA; Elias, FTS
  • Selection of essential medicines and the burden of disease in Brazil
    Figueiredo, TA; Schramm, JMA; Pepe, VLE
  • Implementation of clinical guidelines in Brazil: should academic detailing be used?
    Costa, JO; Almeida‐Brasil, CC; Godman, B; Fischer, MA; Dartnell, J; Heaney, A
  • Adverse drug reactions in Germany: direct costs of internal medicine hospitalizations
    Rottenkolber, D; Schmiedl, S; Rottenkolber, M; Farker, K; Saljé, K; Mueller, S
  • Personalizing health care: feasibility and future implications
    Godman, B; Finlayson, AE; Cheema, PK; Zebedin‐Brandl, E; Gutiérrez‐Ibarluzea, I; Jones, J
  • Rational therapeutics: health‐related elements in lawsuits demanding medicines
    Sant'Ana, JMB; Pepe, VLE; Figueiredo, TA; Osorio‐de‐Castro, CGS
  • Sale strategies of pharmaceutical companies in a “pharmerging” country: the problems will not improve if the gaps remain
    Civaner, M
  • A sanitary focus on medicines lawsuit
    Figueiredo, TA; Pepe, VLE; Osorio‐de‐Castro, CGS
  • Multiple initiatives continue to enhance the prescribing efficiency for the proton pump inhibitors and statins in Scotland
    Bennie, M; Godman, B; Bishop, I; Campbell, S
  • Soft regulations in pharmaceutical policy making an overview of current approaches and their consequences
    Wettermark, B; Godman, B; Jacobsson, B; Haaijer‐Ruskamp, FM
  • Different initiatives across Europe to enhance losartan utilization post generics: impact and implications
    Moon, JC; Godman, B; Petzold, M; Alvarez‐Madrazo, S; Bennett, K; Bishop, I
  • Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden; global relevance
    Godman, B; Wettermark, B; Hoffman, M; Andersson, K; Haycox, A; Gustafsson, LL
  • Interface management of pharmacotherapy. Joint hospital and primary care drug recommendations
    Björkhem‐Bergman, J; Andersen‐Karlsson, E; Laing, R; Diogene, E; Melien, M; Jirlow, M
  • Accelerated approval and expensive drugs: a challenging combination
    Gellad, WF; Kesselheim, AS
  • Introduction and utilization of high priced HCV medicines across Europe; implications for the future
    Bruijn, W; Ibanez, C; Frisk, P; Bak Pedersen, H; Alkan, A; Vella Bonanno, P
  • Public procurement of hepatitis C medicines in Brazil from 2005 to 2015
    Chaves, GC; Osorio‐de‐Castro, CGS; Oliveira, MA
  • An analytical framework for assessing Drug and Therapeutics Committee structure and work processes in tertiary Brazilian hospitals
    Lima‐Dellamora, EC; Caetano, R; Gustafsson, LL; Godman, BB; Patterson, K; Osorio‐de‐Castro, CGS
  • Induction of hospital indebtedness due to medicine purchases under monopoly conditions: the case of imatinib mesylate
    Scopel, CT; Chaves, GC
  • Legal access to medications: a threat to Brazil's public health system?
    Chieffi, AL; Barata, RCB; Golbaum, M
  • Between January 2009 and April 2016, 134 novel anticancer therapies were approved: what is the level of knowledge concerning the clinical benefit at the time of approval?
    Grössmann, N; Wild, C
  • Delivering maximum clinical benefit at an affordable price: engaging stakeholders in cancer care
    Kelly, RJ; Smith, TJ

You’re reading a free preview. Subscribe to read the entire article.

Try 2 weeks free now

DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

or browse the journals available

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial

Interested in DeepDyve for your group?
Try 2 weeks free now